Cancer Genetics closes $2.625 million convertible note financing
Cancer Genetics announced the closing of a $2.625 million convertible note financing with a single institutional investor. The Note is convertible at any time at a fixed price of $0.80 per share and accrues interest at the rate of 10% per annum. July 18, 2018